Merck Q2 2026: Keytruda Growth, Terns and Company Relationships | Stock Spotlight
Merck’s Q2 2026 sales rose 5% to $16.6 billion, while a $5.7 billion Terns charge weighed on earnings. A Phase 3 melanoma milestone and TenderAlpha data on trade flows, counterparties and government awards add context to its post-Keytruda strategy.
Read More